NewAmsterdam Pharma Company NAMS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$212.73M-4.4% | -$203.82M+7.8% | -$221.07M-33.4% | -$165.72M+11.6% | -$187.36M+22.5% | ||
| $230K+4.5% | $220K+3.8% | $212K+20.5% | $176K+17.3% | $150K+32.7% | ||
| $62.21M+4.7% | $59.43M+8.4% | $54.82M+14.7% | $47.8M+16.8% | $40.91M+21.7% | ||
| -$141.92M+4.0% | -$147.78M-2.4% | -$144.39M-16.3% | -$124.12M+11.6% | -$140.43M+11.4% | ||
| $268K+8.9% | $246K+65.1% | $149K-18.1% | $182K-39.9% | $303K-54.9% | ||
| -$191.79M-8.1% | -$177.42M+18.8% | -$218.46M0.0% | -$218.54M-267% | -$59.61M+5.2% | ||
| $34.07M+15.4% | $29.52M-93.8% | $472.45M+1.3% | $466.61M-0.3% | $467.85M-29.1% | ||
| -$297.13M-1.3% | -$293.18M-362% | $112.1M— | —— | —— | ||
| -$142.19M+3.9% | -$148.03M-2.4% | -$144.54M-16.3% | -$124.3M+11.7% | -$140.73M+11.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's cash flow data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.